Search > Results
You searched for: EV200068 (EV-TRACK ID)
Showing 1 - 5 of 5
Showing 1 - 5 of 5
Details | EV-TRACK ID | Experiment nr. | Species | Sample type | Separation protocol | First author | Year | EV-METRIC |
---|---|---|---|---|---|---|---|---|
EV200068 | 1/5 | Homo sapiens | Blood plasma |
(d)(U)C SEC (non-commercial) Filtration |
Linda Hofmann | 2020 | 50% | |
Study summaryFull title
All authors
Linda Hofmann, Sonja Ludwig, Patrick J Schuler, Thomas K Hoffmann, Cornelia Brunner, Marie-Nicole Theodoraki
Journal
Int J Mol Sci
Abstract
Head and neck squamous cell carcinomas (HNSCC) are highly immune suppressive and aggressive malignan (show more...)
EV-METRIC
50% (83rd percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Blood plasma
Sample origin
Control condition
Focus vesicles
exosome
Separation protocol
Separation protocol
(d)(U)C
SEC (non-commercial) Filtration Protein markers
EV: TSG101/ CD81/ CD63/ CD9/ CD16
non-EV: Grp94/ ApoA1 Proteomics
no
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Blood plasma
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 10,000 g and 50,000 g Pelleting performed
No
Filtration steps
0.22µm or 0.2µm
Size-exclusion chromatography
Total column volume (mL)
10
Sample volume/column (mL)
1
Resin type
Sepharose CL-2B
Other
Name other separation method
SEC (non-commercial)
Characterization: Protein analysis
Protein Concentration Method
BCA
Western Blot
Antibody details provided?
Yes
Antibody dilution provided?
Yes
Lysis buffer provided?
Yes
Detected EV-associated proteins
CD9/ CD63/ TSG101/ CD81
Not detected contaminants
ApoA1/ Grp94
Flow cytometry aspecific beads
Antibody details provided?
No
Detected EV-associated proteins
CD16
Flow cytometry specific beads
Antibody details provided?
No
Antibody dilution provided?
No
Selected surface protein(s)
CD44v3
Detected EV-associated proteins
CD16
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Size range/distribution
Reported size (nm)
30-150
EM
EM-type
Transmission-EM
Image type
Wide-field
|
||||||||
EV200068 | 2/5 | Homo sapiens | Blood plasma |
(d)(U)C SEC (non-commercial) Filtration |
Linda Hofmann | 2020 | 50% | |
Study summaryFull title
All authors
Linda Hofmann, Sonja Ludwig, Patrick J Schuler, Thomas K Hoffmann, Cornelia Brunner, Marie-Nicole Theodoraki
Journal
Int J Mol Sci
Abstract
Head and neck squamous cell carcinomas (HNSCC) are highly immune suppressive and aggressive malignan (show more...)
EV-METRIC
50% (83rd percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Blood plasma
Sample origin
HNSCC
Focus vesicles
exosome
Separation protocol
Separation protocol
(d)(U)C
SEC (non-commercial) Filtration Protein markers
EV: TSG101/ CD81/ CD63/ CD9/ CD16
non-EV: Grp94/ ApoA1 Proteomics
no
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Blood plasma
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 10,000 g and 50,000 g Pelleting performed
No
Filtration steps
0.22µm or 0.2µm
Size-exclusion chromatography
Total column volume (mL)
10
Sample volume/column (mL)
1
Resin type
Sepharose CL-2B
Other
Name other separation method
SEC (non-commercial)
Characterization: Protein analysis
Protein Concentration Method
BCA
Western Blot
Antibody details provided?
Yes
Antibody dilution provided?
Yes
Lysis buffer provided?
Yes
Detected EV-associated proteins
CD9/ CD63/ TSG101/ CD81
Not detected contaminants
ApoA1/ Grp94
Flow cytometry aspecific beads
Antibody details provided?
No
Detected EV-associated proteins
CD16
Flow cytometry specific beads
Antibody details provided?
No
Antibody dilution provided?
No
Selected surface protein(s)
CD44v3
Detected EV-associated proteins
CD16
Characterization: Lipid analysis
No
|
||||||||
EV200068 | 3/5 | Homo sapiens | THP-1 |
(d)(U)C SEC (non-commercial) Filtration UF |
Linda Hofmann | 2020 | 15% | |
Study summaryFull title
All authors
Linda Hofmann, Sonja Ludwig, Patrick J Schuler, Thomas K Hoffmann, Cornelia Brunner, Marie-Nicole Theodoraki
Journal
Int J Mol Sci
Abstract
Head and neck squamous cell carcinomas (HNSCC) are highly immune suppressive and aggressive malignan (show more...)
EV-METRIC
15% (53rd percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Cell culture supernatant
Sample origin
Control condition
Focus vesicles
exosome
Separation protocol
Separation protocol
(d)(U)C
SEC (non-commercial) Filtration UF Protein markers
EV: CD16
non-EV: None Proteomics
no
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Cell culture supernatant
EV-producing cells
THP-1
EV-harvesting Medium
EV-depleted serum
Preparation of EDS
Commercial EV-depleted serum
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 10,000 g and 50,000 g Pelleting performed
No
Filtration steps
0.22µm or 0.2µm
Ultra filtration
Cut-off size (kDa)
100
Membrane type
Polyethersulfone (PES)
Size-exclusion chromatography
Total column volume (mL)
10
Sample volume/column (mL)
1
Resin type
Sepharose CL-2B
Other
Name other separation method
SEC (non-commercial)
Characterization: Protein analysis
Protein Concentration Method
BCA
Flow cytometry aspecific beads
Antibody details provided?
No
Detected EV-associated proteins
CD16
Characterization: Lipid analysis
No
|
||||||||
EV200068 | 4/5 | Homo sapiens | PCI-30 |
(d)(U)C SEC (non-commercial) Filtration UF |
Linda Hofmann | 2020 | 15% | |
Study summaryFull title
All authors
Linda Hofmann, Sonja Ludwig, Patrick J Schuler, Thomas K Hoffmann, Cornelia Brunner, Marie-Nicole Theodoraki
Journal
Int J Mol Sci
Abstract
Head and neck squamous cell carcinomas (HNSCC) are highly immune suppressive and aggressive malignan (show more...)
EV-METRIC
15% (53rd percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Cell culture supernatant
Sample origin
Control condition
Focus vesicles
exosome
Separation protocol
Separation protocol
(d)(U)C
SEC (non-commercial) Filtration UF Protein markers
EV: CD16
non-EV: None Proteomics
no
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Cell culture supernatant
EV-producing cells
PCI-30
EV-harvesting Medium
EV-depleted serum
Preparation of EDS
Commercial EV-depleted serum
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 10,000 g and 50,000 g Pelleting performed
No
Filtration steps
0.22µm or 0.2µm
Ultra filtration
Cut-off size (kDa)
100
Membrane type
Polyethersulfone (PES)
Size-exclusion chromatography
Total column volume (mL)
10
Sample volume/column (mL)
1
Resin type
Sepharose CL-2B
Other
Name other separation method
SEC (non-commercial)
Characterization: Protein analysis
Protein Concentration Method
BCA
Flow cytometry aspecific beads
Antibody details provided?
No
Detected EV-associated proteins
CD16
Characterization: Lipid analysis
No
|
||||||||
EV200068 | 5/5 | Homo sapiens | SCC-47 |
(d)(U)C SEC (non-commercial) Filtration UF |
Linda Hofmann | 2020 | 15% | |
Study summaryFull title
All authors
Linda Hofmann, Sonja Ludwig, Patrick J Schuler, Thomas K Hoffmann, Cornelia Brunner, Marie-Nicole Theodoraki
Journal
Int J Mol Sci
Abstract
Head and neck squamous cell carcinomas (HNSCC) are highly immune suppressive and aggressive malignan (show more...)
EV-METRIC
15% (53rd percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Cell culture supernatant
Sample origin
Control condition
Focus vesicles
exosome
Separation protocol
Separation protocol
(d)(U)C
SEC (non-commercial) Filtration UF Protein markers
EV: CD16
non-EV: None Proteomics
no
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Cell culture supernatant
EV-producing cells
SCC-47
EV-harvesting Medium
EV-depleted serum
Preparation of EDS
Commercial EV-depleted serum
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 10,000 g and 50,000 g Pelleting performed
No
Filtration steps
0.22µm or 0.2µm
Ultra filtration
Cut-off size (kDa)
100
Membrane type
Polyethersulfone (PES)
Size-exclusion chromatography
Total column volume (mL)
10
Sample volume/column (mL)
1
Resin type
Sepharose CL-2B
Other
Name other separation method
SEC (non-commercial)
Characterization: Protein analysis
Protein Concentration Method
BCA
Flow cytometry aspecific beads
Antibody details provided?
No
Detected EV-associated proteins
CD16
Characterization: Lipid analysis
No
|
||||||||
1 - 5 of 5 |
EV-TRACK ID | EV200068 | ||||
---|---|---|---|---|---|
species | Homo sapiens | ||||
sample type | Blood plasma | Blood plasma | Cell culture | Cell culture | Cell culture |
cell type | NA | NA | THP-1 | PCI-30 | SCC-47 |
medium | NA | NA | EV-depleted serum | EV-depleted serum | EV-depleted serum |
condition | Control condition | HNSCC | Control condition | Control condition | Control condition |
separation protocol | (d)(U)C SEC (non-commercial) Filtration | (d)(U)C SEC (non-commercial) Filtration | (d)(U)C SEC (non-commercial) Filtration UF | (d)(U)C SEC (non-commercial) Filtration UF | (d)(U)C SEC (non-commercial) Filtration UF |
Exp. nr. | 1 | 2 | 3 | 4 | 5 |
EV-METRIC % | 50 | 50 | 15 | 15 | 15 |